

Gamma Secretase (EC 3.4.23.) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/G7B00F4A04CEN.html>

Date: December 2019

Pages: 78

Price: US\$ 3,500.00 (Single User License)

ID: G7B00F4A04CEN

Abstracts

Gamma Secretase (EC 3.4.23.) - Pipeline Review, H2 2019

SUMMARY

Gamma Secretase (EC 3.4.23.) pipeline Target constitutes close to 21 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The latest report Gamma Secretase (EC 3.4.23.) - Pipeline Review, H2 2019, outlays comprehensive information on the Gamma Secretase (EC 3.4.23.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Gamma Secretase (EC 3.4.23.) - Gamma secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain. The most well-known substrate of gamma secretase is amyloid precursor protein, when cleaved by both gamma and beta secretase, produces a short 39-42 amino acid peptide called amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients. Gamma secretase is also critical in the related processing of the Notch protein.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 11 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Ear Nose Throat Disorders, Cardiovascular and Non Malignant Disorders which include

indications Alzheimer's Disease, Adenoid Cystic Carcinoma (ACC), Hearing Disorders, Lymphoblastic Lymphoma, Metastatic Breast Cancer, Soft Tissue Sarcoma, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), T-Cell Lymphomas, Acute Sensorineural Hearing Loss, Benign Tumor, Bile Duct Cancer (Cholangiocarcinoma), Burkitt Lymphoma, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Colorectal Cancer, Congestive Heart Failure (Heart Failure), Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Hematological Tumor, Leiomyosarcoma, Leukemia, Melanoma, Metastatic Hepatocellular Carcinoma (HCC), Natural Killer Cell Lymphomas, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Solid Tumor, Squamous Non-Small Cell Lung Cancer, T-Cell Leukemia and Triple-Negative Breast Cancer (TNBC).

Furthermore, this report also reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.)

The report reviews Gamma Secretase (EC 3.4.23.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics and enlists all their major and minor projects

The report assesses Gamma Secretase (EC 3.4.23.) targeted therapeutics

based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Gamma Secretase (EC 3.4.23.)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Gamma Secretase (EC 3.4.23.) - Overview

Gamma Secretase (EC 3.4.23.) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Gamma Secretase (EC 3.4.23.) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gamma Secretase (EC 3.4.23.) - Companies Involved in Therapeutics Development

AlzeCure Pharma AB

Astellas Pharma Inc

Audion Therapeutics BV

Ayala Pharmaceuticals Inc

Bristol-Myers Squibb Co

Cotinga Pharmaceuticals Inc

Eli Lilly and Co

Everfront Biotech Inc

Lipopharma Therapeutics SL

Merck & Co Inc

NeuroGenetic Pharmaceuticals Inc

Pharchoice Therapeutics Inc

Pipeline Therapeutics Inc

SpringWorks Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Gamma Secretase (EC 3.4.23.) - Drug Profiles

ACD-679 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACD-680 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AL-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AL-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986133 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crenigacestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EF-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate PSEN1 for Heart Failure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSI-34 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LP-226A1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3056480 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGP-555 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nirogacestat hydrobromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Inhibit PSEN1 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PIPE-505 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Beta and Gamma Secretase for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Gamma Secretase for Hearing Loss - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PSEN1 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Modulate Gamma Secretase for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gamma Secretase (EC 3.4.23.) - Dormant Products

Gamma Secretase (EC 3.4.23.) - Discontinued Products

Gamma Secretase (EC 3.4.23.) - Product Development Milestones

Featured News & Press Releases

Dec 09, 2019: Researchers present preclinical data showing synergistic activity of Springworks Therapeutics gamma secretase inhibitor (Nirogacestat) with glaxosmithkline's BCMA antibody-drug conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH) Annual Meeting

Sep 30, 2019: Ayala Pharmaceuticals presents encouraging preliminary safety and efficacy data in patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with progressing disease and notch activating mutations from ongoing phase 2 clinical trial at ESMO

Sep 26, 2019: SpringWorks receives orphan status for nirogacestat in Europe

Sep 19, 2019: Ayala Pharmaceuticals announces presentation at the European Society for Medical Oncology (ESMO)

Aug 30, 2019: SpringWorks receives breakthrough status for desmoid tumour drug

May 20, 2019: Ayala Pharmaceuticals to present at ASCO Annual Meeting on investigational drug AL101 in adenoid cystic carcinoma and triple negative breast cancer

May 20, 2019: SpringWorks Therapeutics announces initiation of Phase 3 trial (DeFi) of nirogacestat in adult patients with desmoid tumors

May 13, 2019: FDA grants Orphan Drug Designation to Ayala's AL101 for potential treatment of adenoid cystic carcinoma (ACC)

Mar 07, 2019: New drug could restore hearing in the deaf

Mar 06, 2019: Ayala Pharmaceuticals to present preclinical data at AACR for AL101, a pan-notch inhibitor being evaluated for adenoid cystic carcinoma

Feb 05, 2019: Audion Therapeutics and REGAIN consortium announce positive phase I results in patients with sensorineural hearing loss

Dec 17, 2018: Ayala Pharmaceuticals announces first patient enrolled in phase 2 study of lead product candidate AL101 for Adenoid Cystic Carcinoma with notch activated mutations

Nov 07, 2018: SpringWorks Therapeutics receives FDA fast track designation for Nirogacestat for the treatment of adult patients with desmoid tumors

Jan 09, 2017: NeuroGenetic Pharmaceuticals Completes Phase 1 Clinical Trials for NGP 555 to Treat and Prevent Alzheimer's Disease; Shown as Safe and Well-Tolerated in Healthy Volunteers

Nov 10, 2015: NeuroGenetic Pharmaceuticals Awarded \$2.5 Million Grant From NIA to Conduct Clinical Trials with NGP 555 to Treat and Prevent Alzheimer's Disease;

Reports Initial Results of Phase 1a Clinical Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AlzeCure Pharma AB, H2 2019
Pipeline by Astellas Pharma Inc, H2 2019
Pipeline by Audion Therapeutics BV, H2 2019
Pipeline by Ayala Pharmaceuticals Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Cotinga Pharmaceuticals Inc, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Everfront Biotech Inc, H2 2019
Pipeline by Lipopharma Therapeutics SL, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by NeuroGenetic Pharmaceuticals Inc, H2 2019
Pipeline by Pharchoice Therapeutics Inc, H2 2019
Pipeline by Pipeline Therapeutics Inc, H2 2019
Pipeline by SpringWorks Therapeutics Inc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

AlzeCure Pharma AB
Astellas Pharma Inc
Audion Therapeutics BV
Ayala Pharmaceuticals Inc
Bristol-Myers Squibb Co
Cotinga Pharmaceuticals Inc
Eli Lilly and Co
Everfront Biotech Inc
Lipopharma Therapeutics SL
Merck & Co Inc
NeuroGenetic Pharmaceuticals Inc
Pharchoice Therapeutics Inc
Pipeline Therapeutics Inc
SpringWorks Therapeutics Inc
Takeda Pharmaceutical Co Ltd

I would like to order

Product name: Gamma Secretase (EC 3.4.23.) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/G7B00F4A04CEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7B00F4A04CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970